Integrated Diagnostics Holdings's quarterly market cap
increased
from Mar. 2025 ($232.53 Mil) to Dec. 2025 ($433.09 Mil) but then
declined
from Dec. 2025 ($433.09 Mil) to Mar. 2026 ($325.54 Mil).
Integrated Diagnostics Holdings's annual market cap
increased
from Dec. 2023 ($213.00 Mil) to Dec. 2024 ($254.04 Mil) and
increased
from Dec. 2024 ($254.04 Mil) to Dec. 2025 ($433.09 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Integrated Diagnostics Holdings's Enterprise Value for Today is $297.22 Mil.
Integrated Diagnostics Holdings (LSE:IDHC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Integrated Diagnostics Holdings Market Cap Related Terms
Integrated Diagnostics Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Market Cap falls into.
Integrated Diagnostics Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a Market Cap of $291.83 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integrated Diagnostics Holdings and its competitors. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #76 out of 219 companies in the Medical Diagnostics & Research industry, placing it in the top 34.7%.
Is Integrated Diagnostics Holdings' Market Cap too high?
Integrated Diagnostics Holdings' current Market Cap is $291.83 Mil. The Medical Diagnostics & Research industry median Market Cap is 55.76. Integrated Diagnostics Holdings' value of $291.83 Mil is 423.4% above this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #76 out of 219 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #76 out of 219 companies for Market Cap. This puts Integrated Diagnostics Holdings in the upper half of its industry. The industry median Market Cap is 55.76. Integrated Diagnostics Holdings' value of $291.83 Mil is 423.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 55.76, based on 219 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current Market Cap of $291.83 Mil is 423.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 55.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current Market Cap is $291.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current Market Cap is $291.83 Mil and 423.4% above the Medical Diagnostics & Research industry median of 55.76. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Market Cap is $291.83 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
Market Cap: $291.83 Mil
GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
Industry Position: 423.4% above the Medical Diagnostics & Research median (#76 of 219)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
